Cagrilintide + Semaglutide (10mg Blend) Dosage Protocol
Amylin analog (Cagrilintide) + GLP-1 agonist (Semaglutide) blend — investigational (CagriSema), not FDA-approved in this research form.
Mix & measure Cagrilintide + Semaglutide · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
This Cagrilintide + Semaglutide (10 mg blend) vial combines a long-acting amylin analog (Cagrilintide) with a GLP-1 receptor agonist (Semaglutide) in one combined vial — the dual GLP-1 + amylin pairing known commercially as “CagriSema”[1][5]. This educational page outlines a once-weekly subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Neither this compounded blend nor cagrilintide is FDA-approved; CagriSema is investigational and under FDA review (a decision is expected in 2026). Presented for research and educational use only — not a medicine and not medical advice.
Add 3.0 mL bacteriostatic water to the single 10 mg blend vial → ~3.33 mg/mL (3,333 mcg/mL of total blend).
0.25–2.4 mg of total blend once weekly, titrated upward gradually across a 16–week course.
At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg of total blend; 1.0 mg ≈ 30 units and 2.4 mg ≈ 72 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single combined-blend vial, one practical dilution, accurate once-weekly dosing — step by step
Standard / Gradual Approach (3.0 mL ≈ 3.33 mg/mL total blend)
Reconstitute: Add 3.0 mL bacteriostatic water to the single 10 mg blend vial (one combined Cagrilintide + Semaglutide vial) → final concentration ~3.33 mg/mL (3,333 mcg/mL of total blend).
Typical weekly range: 0.25–2.4 mg of total blend once weekly, raised gradually over a 16–week titration.
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg of total blend on a U-100 syringe, so units = mg ÷ 0.0333 (e.g. 1.0 mg ≈ 30 units).
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection once weekly, titrating up gradually as tolerated. Doses are expressed as total blend (combined Cagrilintide + Semaglutide); the exact Cagrilintide-to-Semaglutide ratio is not disclosed for this vial, so per-component milligrams cannot be calculated[3][4]. These titration figures mirror published schedules for the branded CagriSema pharmaceutical and are not approved human dosing for this compounded research blend.
Advanced / Aggressive Approach (3.0 mL ≈ 3.33 mg/mL total blend)
Weeks 1–2: 0.5 mg total blend once weekly — ~15 units (0.15 mL).
Weeks 3–6: 1.0 mg total blend once weekly — ~30 units (0.30 mL).
Weeks 7–10: 1.7 mg total blend once weekly — ~51 units (0.51 mL).
Weeks 11–16 (Maintenance): 2.4 mg total blend once weekly — ~72 units (0.72 mL).
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
At ~3.33 mg/mL, units = mg ÷ 0.0333 (1 unit ≈ 33.3 mcg of total blend). Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume a 16–week once-weekly course with gradual titration. This research blend is not sold here; supplier links are informational only.
One 10 mg blend vial reconstituted at 3.0 mL covers the full titration; total dose used per 16–week cycle stays under the 10 mg supplied.
- 16-week cycle: 1 vial
- Concentration: ~3.33 mg/mL
- Dose basis: total blend, once weekly
- Per injection: 1 syringe
- 16 weeks (once weekly): ~16 syringes
- Use a U-100 1 mL syringe per injection
Use ~3.0 mL to reconstitute the single 10 mg blend vial.
- Per blend vial: ~3.0 mL
- Need: 1 bottle (10 mL)
One for the vial stopper + one for the injection site each week.
- Per injection: 2 swabs
- 16 weeks (once weekly): ~32 swabs → 1 box
Protocol Overview
A concise summary of this once-weekly combined-blend regimen, drawn from titration schedules published for the branded pharmaceutical (not from data on this research blend).
- ▪Goal: Investigate appetite, satiety and glycemic effects of a dual GLP-1 (Semaglutide) + amylin (Cagrilintide) blend — the ~20% weight-loss figures cited for CagriSema come from Novo Nordisk controlled trials of the pharmaceutical, not from this unregulated blend[5][6].
- ▪Schedule: One subcutaneous injection once weekly across a ~16–week titration.
- ▪Dose Range: 0.25 mg up to 2.4 mg of total blend per week, escalated gradually.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 10 mg blend vial gives ~3.33 mg/mL (1 unit ≈ 33.3 mcg total blend).
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A suggested once-weekly titration approach for the total blend, based on published schedules for the branded pharmaceutical.
- ▪Start: Begin at 0.25 mg total blend once weekly (Standard) or 0.5 mg (Advanced) to gauge tolerability.
- ▪Titrate: Step up through 0.5, 1.0, 1.7 mg as tolerated, allowing several weeks at each step.
- ▪Target: Reach the 2.4 mg weekly maintenance dose (~72 units) by week 13–17 (Standard) or week 11 (Advanced).
- ▪Cycle Length: Typically ~16 weeks or longer, depending on research goals.
- ▪Timing: Inject on the same day each week and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep weekly administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log each weekly dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory / approval note: Neither this Cagrilintide + Semaglutide blend nor cagrilintide is FDA-approved; the semaglutide molecule is FDA-approved standalone (Wegovy/Ozempic) but not in this compounded research blend, and CagriSema remains investigational under FDA review. GLP-1/amylin agents are not explicitly named on the WADA Prohibited List, but an unapproved research form warrants S0 (non-approved substance) caution[10].
How This Works
Semaglutide is a GLP-1 receptor agonist: it mimics the incretin hormone GLP-1 to enhance glucose-dependent insulin secretion, slow gastric emptying and reduce appetite[1][2].
Cagrilintide is a long-acting amylin analog. Amylin is co-secreted with insulin and promotes satiety and slowed gastric emptying; cagrilintide extends that signalling to complement the GLP-1 pathway[3].
Combining the two creates a dual GLP-1 + amylin agent — the pairing developed commercially as “CagriSema.” In this vial both peptides are supplied together as a single 10 mg total blend; the Cagrilintide-to-Semaglutide ratio is not disclosed, so doses on this page are stated as total blend and per-component milligrams are unknown.
Approval status (important): Neither this compounded blend nor cagrilintide is FDA-approved. The semaglutide molecule is FDA-approved on its own (Wegovy/Ozempic) but not in this research blend. CagriSema is investigational — under FDA review with a decision expected in 2026, not yet approved[4].
The roughly 20% weight-loss figures attributed to CagriSema come from Novo Nordisk’s controlled trials of the pharmaceutical, not from this unregulated research blend, and should not be read as proven for this product. Presented for research and educational use only — not medical advice.
Lifestyle Factors
Habits that may support metabolic and weight-management goals alongside the protocol.
- ▪Nutrition: Prioritise adequate protein and a moderate calorie deficit so appetite reduction translates into healthy weight change.
- ▪Activity: Combine regular resistance and aerobic exercise to preserve lean mass during weight loss.
- ▪Sleep: Aim for 7–9 hours to support appetite-regulating hormones and metabolic health.
- ▪Stress & hydration: Manage stress and stay well hydrated, especially if GI side effects reduce intake.
Potential Benefits & Side Effects
What controlled trials of the branded CagriSema pharmaceutical describe; this unregulated research blend has not been studied, and individual results vary.
Potential Benefits
- ▪Weight reduction (trial pharmaceutical): Phase trials of the branded CagriSema reported roughly ~20% mean body-weight loss — from the pharmaceutical, not this blend[5][6].
- ▪Glycemic control: The GLP-1 component supports glucose-dependent insulin secretion and improved glycemic markers in studies of the approved molecule[2].
- ▪Appetite & satiety: Dual GLP-1 + amylin signalling is reported to reduce appetite and increase satiety in trial subjects.
- ▪Important: These benefits are not established for this compounded blend — they come from controlled trials of the regulated pharmaceutical, and CagriSema itself remains investigational[4].
Common Side Effects
- ▪GI effects (most common): Nausea, reduced appetite, constipation or diarrhea are the most frequently reported effects of GLP-1/amylin agents; gradual titration helps.
- ▪Injection-site & other: Mild injection-site reactions and headaches can occur; safety of this compounded blend specifically is unstudied, so caution and monitoring are advised.
- ▪Approval / sport note: Not FDA-approved in this research form; as an unapproved substance it warrants WADA S0 caution for athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each week to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides. Note this Cagrilintide + Semaglutide blend is not sold here — the link below goes to the supplier homepage for informational purposes only.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
FDA — Wegovy (semaglutide) Prescribing InformationFDA-approved labeling for the standalone semaglutide molecule (GLP-1 receptor agonist) for chronic weight management.
- 2
NEJM — Semaglutide and Weight Loss (STEP trials)Randomized controlled trial of once-weekly semaglutide for weight management and its metabolic effects.
- 3
The Lancet — Cagrilintide, a long-acting amylin analoguePhase 2 trial of the long-acting amylin analog cagrilintide for weight management.
- 4
Novo Nordisk / NEJM — CagriSema (cagrilintide + semaglutide)Trial data on the investigational dual GLP-1 + amylin combination CagriSema; regulatory status under FDA review.
- 5
The Lancet — CagriSema weight-loss outcomesReported mean body-weight reduction (~20%) with the branded CagriSema pharmaceutical in controlled trials.
- 6
Nature Reviews / Diabetes Obes Metab — Dual GLP-1 + amylin agonismMechanistic review of combining GLP-1 receptor agonism with amylin analog therapy for appetite and satiety.
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
Peptide Reconstitution & StabilityGuidance on reconstituting peptides and refrigerated storage of the mixed solution; avoid freeze–thaw.
- 9
CDC — Safe Injection PracticesRecommendations on sterile single-use syringes and rotation of subcutaneous injection sites.
- 10
FDA — Compounded and Unapproved DrugsFDA guidance on compounded/unapproved drug products and their regulatory status.
- 11
Diabetes, Obesity and Metabolism — GI tolerability of incretin therapiesReview of gastrointestinal side effects (nausea, GI discomfort) of GLP-1-based therapies and titration strategies.
- 12
Pharmacokinetics of long-acting incretin analogsPharmacokinetic basis for once-weekly subcutaneous dosing of semaglutide and cagrilintide.
- 13
WADA — Prohibited ListWorld Anti-Doping Agency Prohibited List; unapproved substances fall under S0 (non-approved substances).
- 14
Clinical best practice — subcutaneous injection techniqueEstablished guidance on subcutaneous injection angle, technique and site selection.
- 15
Injection site preparation & antisepsisBest-practice guidance on skin antisepsis and air-drying before subcutaneous injection.
- 16
Subcutaneous injection — do not aspirateGuidance that aspiration is not required for routine subcutaneous injections.
How to reconstitute Cagrilintide + Semaglutide
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the Cagrilintide + Semaglutide vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
Cagrilintide + Semaglutide — frequently asked questions
How do I reconstitute a 10 mg vial of Cagrilintide + Semaglutide?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Cagrilintide + Semaglutide?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Cagrilintide + Semaglutide after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of Cagrilintide + Semaglutide provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Cagrilintide + Semaglutide approved for human use?
No. Cagrilintide + Semaglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.